Standard
Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma. / Praetorius, Katrine; Henriksen, Daniel P.; Schmid, Johannes M.; Printzlau, Pernille; Pedersen, Lars; Madsen, Hanne; Andersson, Ehm A.; Madsen, Louise Klokker; Chawes, Bo L.
I:
ERJ Open Research, Bind 7, Nr. 3, 00306-2021, 2021.
Publikation: Bidrag til tidsskrift › Leder › Forskning › fagfællebedømt
Harvard
Praetorius, K, Henriksen, DP, Schmid, JM, Printzlau, P, Pedersen, L, Madsen, H, Andersson, EA, Madsen, LK
& Chawes, BL 2021, '
Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma',
ERJ Open Research, bind 7, nr. 3, 00306-2021.
https://doi.org/10.1183/23120541.00306-2021APA
Praetorius, K., Henriksen, D. P., Schmid, J. M., Printzlau, P., Pedersen, L., Madsen, H., Andersson, E. A., Madsen, L. K.
, & Chawes, B. L. (2021).
Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma.
ERJ Open Research,
7(3), [00306-2021].
https://doi.org/10.1183/23120541.00306-2021Vancouver
Praetorius K, Henriksen DP, Schmid JM, Printzlau P, Pedersen L, Madsen H o.a.
Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma.
ERJ Open Research. 2021;7(3). 00306-2021.
https://doi.org/10.1183/23120541.00306-2021Author
Praetorius, Katrine ; Henriksen, Daniel P. ; Schmid, Johannes M. ; Printzlau, Pernille ; Pedersen, Lars ; Madsen, Hanne ; Andersson, Ehm A. ; Madsen, Louise Klokker ; Chawes, Bo L. / Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma. I: ERJ Open Research. 2021 ; Bind 7, Nr. 3.
Bibtex
@article{4cce2cc759cc4ad4a20a5be61556b24d,
title = "Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma",
keywords = "QUALITY-OF-LIFE, ADD-ON THERAPY, ANTIIMMUNOGLOBULIN-E THERAPY, SEVERE ALLERGIC-ASTHMA, LONG-TERM CONTROL, DOUBLE-BLIND, ANTIBODY OMALIZUMAB, PERSISTENT ASTHMA, MODERATE, MULTICENTER",
author = "Katrine Praetorius and Henriksen, {Daniel P.} and Schmid, {Johannes M.} and Pernille Printzlau and Lars Pedersen and Hanne Madsen and Andersson, {Ehm A.} and Madsen, {Louise Klokker} and Chawes, {Bo L.}",
year = "2021",
doi = "10.1183/23120541.00306-2021",
language = "English",
volume = "7",
journal = "ERJ Open Research",
issn = "2312-0541",
publisher = "ERS publications",
number = "3",
}
RIS
TY - JOUR
T1 - Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma
AU - Praetorius, Katrine
AU - Henriksen, Daniel P.
AU - Schmid, Johannes M.
AU - Printzlau, Pernille
AU - Pedersen, Lars
AU - Madsen, Hanne
AU - Andersson, Ehm A.
AU - Madsen, Louise Klokker
AU - Chawes, Bo L.
PY - 2021
Y1 - 2021
KW - QUALITY-OF-LIFE
KW - ADD-ON THERAPY
KW - ANTIIMMUNOGLOBULIN-E THERAPY
KW - SEVERE ALLERGIC-ASTHMA
KW - LONG-TERM CONTROL
KW - DOUBLE-BLIND
KW - ANTIBODY OMALIZUMAB
KW - PERSISTENT ASTHMA
KW - MODERATE
KW - MULTICENTER
U2 - 10.1183/23120541.00306-2021
DO - 10.1183/23120541.00306-2021
M3 - Editorial
C2 - 34476242
VL - 7
JO - ERJ Open Research
JF - ERJ Open Research
SN - 2312-0541
IS - 3
M1 - 00306-2021
ER -
